Time Zone Converter
Module Two: Impact of Technology Evolution on Ion Channel Drug Discovery
Presented by: Ronald J. Knox Ph.D, Bristol-Myers Squibb Research
This module will examine the research and development story of major classes of marketed ion channel drugs in the context of the critical technologies which enabled their discovery. Two examples which figure prominently in both modern cardiovascular medicine, and in the development of technology strategies for prosecuting ion channel targets broadly, are the quinidine class of Na+-channel blockers, and the dihydropyridine class of Ca++-channel blockers. Na+ channel blocking anti-arrhythmic drugs only exhibit a tolerable therapeutic index due to their innate property of state-dependent binding to specific ion channels.
Meet Our Presenter
Dr. Ronald Knox is currently a Group Leader of Lead Evaluation & Ion Channel Technologies at Bristol-Myers Squibb (BMS) at their Wallingford site in Connecticut, USA. These groups are responsible for all of the high throughput in vitro lead optimization SAR assays for Neuroscience & Virology for BMS. Prior to joining BMS, he conducted post doctoral studies in the area of ion channel modulation at Yale University. Dr. Knox obtained his Bachelor of Science degree in Pharmacology at Glasgow University, Scotland and his Ph.D, studying opioid receptor regulation of nociceptive spinal neurotransmission at University College London, England.
Like this article? Click here to subscribe to free newsletters from Lab Manager